专利检索 ap:("Simon Kullmann" OR "Ulrich Westedt" OR "Mirko Pauli" OR "Rudolf Schroeder" OR "Gerd Woehrle" OR "Tanja Heitermann" OR "Renato Koenig" OR "Madlen Thiel" OR "Yi Gao" OR "Jianwei Wu" OR "Bryan K. Erickson") AND inv:"Madlen Thiel" 第 1 页

1.

发明申请
SOLID COMPOSITIONS 有权
标题翻译：固体组合物

公开(公告)号：US20120264780A1

公开(公告)日：2012-10-18

申请号：US13156793

申请日：2011-06-09

申请人： Simon Kullmann , Ulrich Westedt , Mirko Pauli , Rudolf Schroeder , Gerd Woehrle , Tanja Heitermann , Renato Koenig , Madlen Thiel , Yi Gao , Jianwei Wu , Bryan K. Erickson

发明人： Simon Kullmann , Ulrich Westedt , Mirko Pauli , Rudolf Schroeder , Gerd Woehrle , Tanja Heitermann , Renato Koenig , Madlen Thiel , Yi Gao , Jianwei Wu , Bryan K. Erickson

IPC分类号： A61K31/4545 , A61P31/14 , A61K31/4184

CPC分类号： C07D401/14 , C07D403/14 , C07D417/14

摘要： The present invention features solid compositions comprising Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

摘要翻译： 本发明的特征在于包含无定形形式的化合物1A，IB或IC或其药学上可接受的盐的固体组合物。在一个实施方案中，将化合物1A，IB或IC或其药学上可接受的盐配制在包含药学上可接受的亲水性聚合物，优选药学上可接受的表面活性剂的无定形固体分散体中。

2.

发明授权
Solid compositions 有权
标题翻译：固体成分

公开(公告)号：US08716454B2

公开(公告)日：2014-05-06

申请号：US13156793

申请日：2011-06-09

申请人： Simon Kullmann , Ulrich Westedt , Mirko Pauli , Rudolf Schroeder , Gerd Woehrle , Tanja Heitermann , Renato Koenig , Madlen Thiel , Yi Gao , Jianwei Wu , Bryan K. Erickson

发明人： Simon Kullmann , Ulrich Westedt , Mirko Pauli , Rudolf Schroeder , Gerd Woehrle , Tanja Heitermann , Renato Koenig , Madlen Thiel , Yi Gao , Jianwei Wu , Bryan K. Erickson

IPC分类号： C07K16/00 , A61K38/00

CPC分类号： C07D401/14 , C07D403/14 , C07D417/14

摘要： The present invention features solid compositions comprising Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

摘要翻译： 本发明的特征在于包含无定形形式的化合物1A，IB或IC或其药学上可接受的盐的固体组合物。在一个实施方案中，将化合物1A，IB或IC或其药学上可接受的盐配制在包含药学上可接受的亲水性聚合物，优选药学上可接受的表面活性剂的无定形固体分散体中。